

Atty. Docket No. 178 US

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed May 17, 2000, Applicants request that the following amendments and remarks be made of record in the above-captioned patent application.

Please amend the application as follows:

IN THE CLAIMS

- ~~Please cancel claims 2 and 20.~~
- ~~Claim 19, line 2, please delete "21 or 22" and insert in lieu thereof --28 or 29--.~~
- ~~NE~~ Claim 20, line 2, please delete "21 or 22" and insert in lieu thereof --28 or 29--.

Please amend claim 28 as follows:

- 6 28. (AMENDED) An isolated, enriched or purified nucleic acid molecule comprising a nucleotide sequence that
- (a) encodes a polypeptide [that differs from the polypeptide] having the full-length amino acid sequence set forth in SEQ ID NO:36 [by lacking] except that it lacks one or more, but not all, of the domains selected from the group consisting of an N-terminal domain, a catalytic domain and a C-terminal region; or
  - (b) is the complement of the nucleotide sequence of (a).

E [Please amend claim 29 as follows:]

- 7 29. (AMENDED) An isolated, enriched or purified nucleic acid molecule comprising a nucleotide sequence that
- (a) encodes a polypeptide [that differs from the polypeptide] having the amino acid sequence set forth in SEQ ID NO:36 [by lacking] except that it lacks one or more, but not all, of the following segments of amino acid residues: 1-58, 59-294 or 295-459;
  - (b) is the complement of the nucleotide sequence of (a);
  - (c) encodes a polypeptide having at least one of the amino acid residues 1-58, 59-294 or 295-459 of SEQ ID NO: 36; or
  - (d) is the complement of the nucleotide sequence of (c).